Brian Druker: My Vision for CML and the Road to a Cure

Published on

Topics include: Treatments

Dr. Brian Druker, a CML expert from OHSU's Knight Cancer Institute and a key researcher responsible for the development of imatinib, gives his perspective about the progress that's been made in research and treatment.  He is encouraged that, in most cases, patients can have their disease well managed on existing therapies, while newer agents--some still in trials--will provide even more options for those who are resistant or are experiencing side effects.  Dr. Druker explains that he believes CML research can, and should, begin focusing on eradicating the disease altogther, and provides his suggestion about how he believes that might happen.

View more programs featuring

Transcript

 

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor.  Please have this discussion you’re your own doctor, that’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

But to me the biggest challenge is can we ultimately think about a strategy to eradicate the disease so that people don’t have to be on a daily medication for the rest of their lives.  But it’s still good news that we’ve gone from what was a death sentence 10 years ago to a manageable condition.

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on